AUNA Quote, Financials, Valuation and Earnings

Eurofins Scientific SE has a net margin of 2.26% compared to Auna SA's net margin of --. Auna SA's return on equity of 6.56% beat Eurofins Scientific SE's return on equity of 7.71%.

Auna SA has a consensus price target of $13.35, signalling upside risk potential of 97.78%. On the other hand Eurofins Scientific SE has an analysts' consensus of -- which suggests that it could fall by --. Given that Auna SA has higher upside potential than Eurofins Scientific SE, analysts believe Auna SA is more attractive than Eurofins Scientific SE.

Auna SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eurofins Scientific SE has a beta of 0.731, suggesting its less volatile than the S&P 500 by 26.881%.

Auna SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eurofins Scientific SE offers a yield of 1.01% to investors and pays a quarterly dividend of $0.54 per share. Auna SA pays 0.81% of its earnings as a dividend. Eurofins Scientific SE pays out 23.52% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Auna SA quarterly revenues are $285.9M, which are larger than Eurofins Scientific SE quarterly revenues of --. Auna SA's net income of $6.5M is higher than Eurofins Scientific SE's net income of --. Notably, Auna SA's price-to-earnings ratio is 18.05x while Eurofins Scientific SE's PE ratio is 23.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Auna SA is 0.43x versus 1.39x for Eurofins Scientific SE. Usually stocks with elevated PS ratios are considered overvalued.

Lineage Cell Therapeutics has a net margin of 2.26% compared to Auna SA's net margin of -114.12%. Auna SA's return on equity of 6.56% beat Lineage Cell Therapeutics's return on equity of -27.23%.

Auna SA has a consensus price target of $13.35, signalling upside risk potential of 97.78%. On the other hand Lineage Cell Therapeutics has an analysts' consensus of $3.92 which suggests that it could grow by 733.69%. Given that Lineage Cell Therapeutics has higher upside potential than Auna SA, analysts believe Lineage Cell Therapeutics is more attractive than Auna SA.

Auna SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Lineage Cell Therapeutics has a beta of 1.323, suggesting its more volatile than the S&P 500 by 32.28%.

Auna SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lineage Cell Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Auna SA pays 0.81% of its earnings as a dividend. Lineage Cell Therapeutics pays out -- of its earnings as a dividend. Auna SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Auna SA quarterly revenues are $285.9M, which are larger than Lineage Cell Therapeutics quarterly revenues of $2.9M. Auna SA's net income of $6.5M is higher than Lineage Cell Therapeutics's net income of -$3.3M. Notably, Auna SA's price-to-earnings ratio is 18.05x while Lineage Cell Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Auna SA is 0.43x versus 9.90x for Lineage Cell Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Moolec Science SA has a net margin of 2.26% compared to Auna SA's net margin of -166.47%. Auna SA's return on equity of 6.56% beat Moolec Science SA's return on equity of -93.42%.

Auna SA has a consensus price target of $13.35, signalling upside risk potential of 97.78%. On the other hand Moolec Science SA has an analysts' consensus of -- which suggests that it could grow by 347.69%. Given that Moolec Science SA has higher upside potential than Auna SA, analysts believe Moolec Science SA is more attractive than Auna SA.

Auna SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moolec Science SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Auna SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moolec Science SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Auna SA pays 0.81% of its earnings as a dividend. Moolec Science SA pays out -- of its earnings as a dividend. Auna SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Auna SA quarterly revenues are $285.9M, which are larger than Moolec Science SA quarterly revenues of $1.5M. Auna SA's net income of $6.5M is higher than Moolec Science SA's net income of -$2.5M. Notably, Auna SA's price-to-earnings ratio is 18.05x while Moolec Science SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Auna SA is 0.43x versus 4.69x for Moolec Science SA. Usually stocks with elevated PS ratios are considered overvalued.